RBT will focus on vaccine development projects, where it will control the full cycle — from the development of its own antigen to the finished product. One of these areas is a range of high—margin vaccines for animals. Company also plans to switch to a licensed business model with the transfer of rights to drugs before obtaining a registration certificate.